Previous 10 | Next 10 |
NEW YORK , Aug. 5, 2019 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today provided an update on clinical and corporate developments, includin...
Gainers: Midatech Pharma (NASDAQ: MTP ) +42% . Rayonier Advanced Materials (NYSE: RYAM ) +20% . Gannett (NYSE: GCI ) +19% . CrowdStrike Holdings (NASDAQ: CRWD ) +15% . Camber Energy (NYSEMKT: CEI ) +14% . Skechers U.S.A. (NYSE: SKX ) +13% . Powerbridge Technologies (NASDAQ: PBT...
Neurotrope Inc. (NTRP) is currently testing bryostatin-1 (bryostatin) in patients with moderate to advanced Alzheimer's disease ((AD)) patients (MMSE scores of 4-15). Considering that neurodegeneration begins decades before symptoms appear, these patients are the hardest to improve. Neurotrope...
NEW YORK , July 17, 2019 /PRNewswire/ -- Neurotrope Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that two of the Company's Scientific Advisory Board membe...
NEW YORK , July 15, 2019 /PRNewswire/ -- Neurotrope Inc. (Nasdaq: NTRP ), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that the Company has concluded data collection in its c...
NEW YORK , July 11, 2019 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP), a clinical- stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases, including Alzheimer's disease ("AD") is announcing that Dr. Daniel L. Alkon , the Company's President a...
Protein kinase C is one of the most important enzymes in Alzheimer’s disease, but also one of the trickiest. This enzyme maintains the balance between cell growth and cell death ( review of protein kinase C ). The over-activation of protein kinase C during the early stages of Alzheimer&...
NEW YORK , June 24, 2019 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), announced that Dr. Charles S. Ryan , CEO, will be a featured prese...
The following slide deck was published by Neurotrope, Inc. in conjunction with this Read more ...
NEW YORK , June 3, 2019 /PRNewswire/ -- Neurotrope, Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), announced that Dr. Daniel L. Alkon , the Company's President and CSO, wi...
News, Short Squeeze, Breakout and More Instantly...
SUNRISE, FL / ACCESSWIRE / July 19, 2024 / NextTrip, Inc. (NASDAQ:NTRP) ("NextTrip," "we," "our," or the "Company"), a travel technology company, received a notice (the "Notice") from the listing qualifications department of the Nasdaq Stock Market LLC ("Nasdaq") on July 17, 2024 stating the...
Dynamic Content-to-Commerce FAST Channel Reinvents Monetization Models SUNRISE, FL / ACCESSWIRE / July 18, 2024 / NextTrip, Inc. (NASDAQ:NTRP) ("NextTrip," "we," "our," or the "Company"), a travel technology company, today announced that it has partnered with OTT ("over-the-top") services...
Allows Consumers to Pay for Accommodations Through Interest-free Installments with Convenient and Flexible Payment Options when Booking Travel Seamless Integration Enables Marketing Opportunities in Social Media Travel Package Campaigns and Direct-to-Consumer Marketing Channels to Drive Sale...